Categories Health Care, LATEST
Affimed’s stock tanks as company announces termination of cancer program
Affimed NV (NASDAQ: AFMD) reported first-quarter 2019 earnings results and announced its plans to terminate its cancer program while focusing its R&D resources on its immunity portfolio. Shares plummeted 9.6% in premarket hours on Wednesday.
Total revenue grew to EUR11.4 million from EUR0.5 million in the same period last year, mainly due to the recognition of EUR10.6 million as revenue from the Genentech collaboration.
The company reported a net income of EUR1.9 million, or EUR0.03 per common share, compared to a net loss of EUR8.2 million, or EUR0.15 per common share, for the year-ago period. Net income was primarily related to significantly increased revenue, partially offset by higher R&D and G&A expenses.

R&D expenses rose to EUR8 million from EUR6.4 million last year, mainly driven by higher expenses related to clinical study startup activities for AFM13, as well as early stage development and discovery activities.
Affimed announced its plan to focus its R&D efforts on the clinical trials for its innate cell engager candidates, AFM13 and AFM24. As part of this plan, the company decided to terminate the Phase 1 clinical program of its T cell engager AFM11.
“We are focused on advancing our CD16A-targeting innate cell engager product candidates as we progress through 2019, with the goals of initiating a market registration-directed study of AFM13 and entering the clinic with AFM24,” said CEO Dr. Adi Hoess in a statement.
During the quarter, Affimed received a milestone payment from Genentech as part of its research collaboration to develop and commercialize novel natural killer (NK) cell engager-based immunotherapeutics based on Affimed’s ROCK platform to treat multiple cancers.
Affimed also stated that Dr. Martin Treder intends to step down as Chief Scientific Officer in order to pursue new opportunities but will continue to serve as a consultant.
Most Popular
MU Earnings Preview: Strong Q2 results in cards amid growing AI demand
Micron Technology, Inc. (NASDAQ: MU) is uniquely positioned to capitalize on the AI wave sweeping the tech industry, leveraging its high-bandwidth-memory products designed for massive data processing tasks. The company
What to look for when FedEx (FDX) reports Q3 2025 earnings results
Shares of FedEx Corp. (NYSE: FDX) stayed green on Friday. The stock has dropped 14% over the past three months. The package delivery company is scheduled to report its third
Docusign (DOCU) Earnings: 4Q25 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to